Novel antifolate combination therapies
OwnerClet Niyikizainventor
Life of this patent
Estimating the term…
Abstract
A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
Claims10
1-2. (canceled)
A method of inhibiting tumor growth in humans comprising administering to said human an effective amount of pemetrexed disodium in combination with a methylmalonic acid lowering agent selected from the group consisting of vitamin B12, hydroxocobalamin, cyano-10-chlorocobalamin aquocobalamin perchlorate, aquo-10-chlorocobalamin perchlorate, azidocobalamin, chlorocobalamin, cobalamin, and cyanocobalamin wherein the methylmalonic acid lowering agent is administered prior to the first administration of pemetrexed and the methylmalonic acid lowering agent administration is repeated from about every 6 weeks to about every 12 weeks.
4-33. (canceled)
The method of claim 38 wherein about 500 μg to about 1000 μg of the methylmalonic acid lowering agent is administered.
A method of inhibiting tumor growth in humans comprising administering an effective amount of pemetrexed disodium in combination with about 500 μg to about 1500 μg of a methylmalonic acid lowering agent selected from the group consisting of vitamin B12, hydroxocobalamin, cyano-10-chlorocobalamin, aquocobalamin perchlorate, aquo-10-chlorocobalamin perchlorate, azidocobalamin, chlorocobalamin, cobalamin, and cyanocobalamin wherein the treatment with the methylmalonic acid lowering agent is administered by an intramuscular injection or orally and is repeated from about every 24 hours to about every 1680 hours, until treatment with pemetrexed disodium has ended.
Dependencies are inferred from the claim text.